Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.

Although mutations of the breast cancer susceptibility gene 1 (BRCA1) may play important roles in breast and prostate cancers, the detailed mechanism linking the functions of BRCA1 to these two hormone-related tumors remains to be elucidated. Here, we report that BRCA1 interacts with androgen receptor (AR) and enhances AR target genes, such as p21((WAF1/CIP1)), that may result in the increase of androgen-induced cell death in prostate cancer cells. The BRCA1-enhanced AR transactivation can be further induced synergistically with AR coregulators, such as CBP, ARA55, and ARA70. Together, these data suggest that the BRCA1 may function as an AR coregulator and play positive roles in androgen-induced cell death in prostate cancer cells and other androgen/AR target organs.

[1]  Chawnshang Chang,et al.  Molecular cloning of human and rat complementary DNA encoding androgen receptors. , 1988, Science.

[2]  J. Trachtenberg,et al.  Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor , 1997, Molecular and Cellular Endocrinology.

[3]  J. Parvin,et al.  Activation of Transcription in Vitro by the BRCA1 Carboxyl-terminal Domain* , 1999, The Journal of Biological Chemistry.

[4]  S. Yeh,et al.  Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Tsai,et al.  Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. , 1999, Molecular endocrinology.

[6]  J. Simard,et al.  Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. , 1991, Cancer research.

[7]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[8]  Yanfen Hu,et al.  Chromatin remodeling and activation of chromosomal DNA replication by an acidic transcriptional activation domain from BRCA1. , 1999, Genes & development.

[9]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  John Calvin Reed,et al.  Effect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells , 1999, Oncogene.

[11]  V. Kuenen-Boumeester,et al.  Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer , 1992, International journal of cancer.

[12]  Hui Tian,et al.  BRCA1 physically associates with p53 and stimulates its transcriptional activity , 1998, Oncogene.

[13]  C. Wang,et al.  Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. , 1999, Science.

[14]  A. Kilicyazgan,et al.  Endocrine , 1993, Emergencies in Clinical Medicine.

[15]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[16]  M. T. Abreu-Martin,et al.  Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer , 1999, Molecular and Cellular Biology.

[17]  H. T. Chen,et al.  A point mutation in the second zinc finger of the DNA-binding domain of the androgen receptor gene causes complete androgen insensitivity in two siblings with receptor-positive androgen resistance. , 1993, Molecular endocrinology.

[18]  N. Olsen,et al.  Induction of immature thymocyte proliferation after castration of normal male mice. , 1994, Endocrinology.

[19]  S. Yeh,et al.  Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. , 1998, Biochemical and biophysical research communications.

[20]  James Brugarolas,et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.

[21]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[22]  S. Yeh,et al.  Cloning and Characterization of Human Prostate Coactivator ARA54, a Novel Protein That Associates with the Androgen Receptor* , 1999, The Journal of Biological Chemistry.

[23]  J. Klijn,et al.  Rapid detection of BRCA1 mutations by the protein truncation test , 1995, Nature Genetics.

[24]  N. Olsen,et al.  Androgens accelerate thymocyte apoptosis. , 1998, Endocrinology.

[25]  J. Trapman,et al.  An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. , 1997, Molecular endocrinology.

[26]  S. Inui,et al.  Cloning and Characterization of Androgen Receptor Coactivator, ARA55, in Human Prostate* , 1999, The Journal of Biological Chemistry.

[27]  T. Hunter,et al.  Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells , 1998, Oncogene.

[28]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[29]  C. Sonnenschein,et al.  Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. , 1997, Endocrinology.

[30]  A. Saltzman,et al.  Androgen receptor: an overview. , 1995, Critical reviews in eukaryotic gene expression.

[31]  P. Chambon,et al.  The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. , 1989, Nucleic acids research.

[32]  Chawnshang Chang,et al.  The Linkage of Kennedy’s Neuron Disease to ARA24, the First Identified Androgen Receptor Polyglutamine Region-associated Coactivator* , 1999, The Journal of Biological Chemistry.

[33]  P. Chambon,et al.  Steroid hormone receptors compete for factors that mediate their enhancer function , 1989, Cell.

[34]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[35]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[36]  M. King,et al.  Growth retardation and tumour inhibition by BRCA1 , 1996, Nature Genetics.

[37]  H. Ponta,et al.  The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. , 1987, The EMBO journal.

[38]  Chawnshang Chang,et al.  Isolation and Characterization of ARA160 as the First Androgen Receptor N-terminal-associated Coactivator in Human Prostate Cells* , 1999, The Journal of Biological Chemistry.

[39]  J. Parvin,et al.  BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A , 1998, Nature Genetics.

[40]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[41]  J. Rossant,et al.  The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the Mouse , 1996, Cell.

[42]  P E Wright,et al.  Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.